Press Release

VYLUMA COMPLETES LAST PATIENT VISIT FOR PRIMARY ANALYSIS OF PIVOTAL PHASE III CHAMP STUDY EVALUATING NVK002 FOR THE TREATMENT OF MYOPIA PROGRESSION IN CHILDREN

Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries

Nevakar Announces Closing of $12 Million Convertible Note and Extension of Interest- Only Period with Oxford Finance

VYLUMA AND MYMYOPIA.COM SUPPORT 2021 WORLD SIGHT DAY TO RAISE AWARENESS OF VISION DISORDERS

VYLUMA INC LAUNCHES WITH ROBUST OPHTHALMIC PORTFOLIO, LEADING WITH A PHARMACEUTICAL TREATMENT IN PHASE III FOR MYOPIA

NEVAKAR AND THÉA ENTER INTO LICENSING AGREEMENT FOR THE COMMERCIALIZATION OF NVK002 (ATROPINE FOR THE TREATMENT OF THE PROGRESSION OF MYOPIA IN CHILDREN) IN EUROPE

American Academy of ophthalmology leads global initiative to address worldwide myopia epidemic

FIRST PATIENT COMPLETES THREE YEAR ENROLLMENT IN NEVAKAR’S PHASE III CHAMP STUDY OF NVK002 EVALUATING LOW-DOSE ATROPINE OPHTHALMIC SOLUTION FOR THE TREATMENT OF MYOPIA IN CHILDREN